Iron Deficiency Education and Awareness Act
Legislative Progress
Introduced
December 13, 2023
Latest Action
December 15, 2023
Primary Sponsor
Yadira CaraveoDemocratic(CO)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
58pct
2d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2024 · fourth_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097) FDA guidance impacting hematology
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2024 · third_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097)
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2024 · second_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Comprehensive Care Act (H.R. 7432) H.Res. 1180, re: diversity, equity and inclusion in medical education
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2024 · first_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Comprehensive Care Act (H.R. 7432)
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2023 · fourth_quarter · Energy/Nuclear
H.R. 5551/S. 2827, BIG WIRES Act (whole bill); H.R. 6746, Clean Electricity and Transmission Acceleration Act, provisions related to transmission planning, cost allocation and permitting; S. 1399, Building American Energy Security Act, provisions related to transmission siting and cost allocation. S. 2651, the SITE Act, provisions related to transmission siting and permitting; Draft legislation related to cybersecurity; Draft legislation related to transmission; FERC issues generally; Issues related to energy grid supply chain; Issues related to Federal Power Act generally; Issues related to Infrastructure Investment & Jobs Act Implementation; Issues related to minimum transfer capacity; Issues relating to transmission siting and permitting generally.
Client expense: $200,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Federal Energy Regulatory Commission (FERC), HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746)
Client expense: $30,000 · Firm income: Not reported
2023 · fourth_quarter · Health Issues
Abortion access (general); Access to Mifepristone (general); Contraception (general); Maternal Mortality and Morbidity (general); H.R. 1117, Advancing Safe Medications for Moms and Babies Act; obstetric and gynecologic care in rural and underserved areas (general); H.R. 3305/S. 1606, Black Maternal Health Momnibus Act; H.R. 1202/S. 704, Resident Education Deferred Interest (REDI) Act; H.R. 2389/S. 1302, Resident Physician Shortage Reduction Act of 2023; H.R. 2569, Doctors of Community (DOC) Act; Teaching Health Center Graduate Medication Education (general); H.R. 3838/S. 2415, Preventing Maternal Deaths Reauthorization Act of 2023; H.R. 3226/S. 1573, PREEMIE Reauthorization Act of 2023; inclusion of pregnant and lactating individuals in research (general); telemedicine (general); H.R. 5012/S. 2647, SHINE for Autumn Act; Rural Residency Planning and Development (RRPD) Program; H.R. 4581/S. 2231, Maternal and Child Health Stillbirth Prevention Act; Health Insurance Portability and Accountability Act (general); patient-physician relationship (general); Cost-sharing for maternity care (general); menopause research (general); Alliance for Innovation on Maternal Health; Residency programs in obstetrics and gynecology (general); Abortion training in obstetrics and gynecology residency programs (general); Obstetrician-gynecologist workforce (general); H.R. 5568/S. 2846, CARE for Moms Act; H.R. 5909, Caring for Grieving Families Act of 2023; S. 3509, Healthy MOM Act; H.R. 6746, Iron Deficiency Education and Awareness Act; H.R. 6743, WARM Act; H.R. 6103/S. 3137, Support Through Loss Act; S. 3070, Youth Prevention and Recovery Authorization Act of 2023; reproductive health data privacy (general); Treatment of reproductive health information under the Stored Communications Act (general); Tax treatment of stillbirths (general); Substance use disorder during pregnancy (general); Physician burnout (general); Maternal mental health (general); Artificial intelligence in health care (general); Coverage for infertility (general); Restrictions on menthol cigarettes and flavored cigars (general); Obstetric unit closures (general); Doxycycline Post-Exposure Prophylaxis (general); White House Initiative on Womens Health Research (general); Plans of Safe Care (general); Section 504 nondiscrimination on the basis of disability (general)
2023 · first_quarter · Retirement
PL 117-328 Consolidated Appropriations Act, 2023 - SECURE 2.0 HR 6746 (117th) Lifetime Income For Employees Act - allows fiduciaries of pension plans to make default investment arrangements in annuity contracts Issue Investment Advice Standards Issue Davis Bacon HR 7151 (117th) Ensuring Sound Guidance Act - Under ERISA, specify that only pecuniary factors are to be taken into account in determining best interest Issue Retirement Security HR 1177/S 427 Financial Freedom Act of 2023 - prohibit the Secretary of Labor from constraining the range or type of investments that may be offered in retirement accounts
Client expense: $980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Securities & Exchange Commission (SEC)
2023 · first_quarter · Retirement
PL 117-328 Consolidated Appropriations Act, 2023 - SECURE 2.0 HR 6746 (117th) Lifetime Income For Employees Act - allows fiduciaries of pension plans to make default investment arrangements in annuity contracts Issue Investment Advice Standards Issue Davis Bacon HR 7151 (117th) Ensuring Sound Guidance Act - Under ERISA, specify that only pecuniary factors are to be taken into account in determining best interest Issue Retirement Security HR 1177/S 427 Financial Freedom Act of 2023 - prohibit the Secretary of Labor from constraining the range or type of investments that may be offered in retirement accounts
Client expense: $980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Securities & Exchange Commission (SEC)
| Democratic |
| MD |
| Jesús G. "Chuy" García | Democratic | IL |
| Jill N. Tokuda | Democratic | HI |
| Mikie Sherrill | Democratic | NJ |
| Nikki Budzinski | Democratic | IL |
| Raúl M. Grijalva | Democratic | AZ |
| Terri A. Sewell | Democratic | AL |
| Troy A. Carter | Democratic | LA |
| Yvette D. Clarke | Democratic | NY |
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office